Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival

European Journal of Cardio-thoracic Surgery

Volumn 36, Issue 3, 2009, Pages 433-439

  Decaluwé, Herbert ^a   De Leyn, Paul ^a   Vansteenkiste, Johan ^a   Dooms, Christophe ^a   Van Raemdonck, Dirk ^a   Nafteux, Philippe ^a   Coosemans, Willy ^a   Lerut, Toni ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Induction therapy; Lobectomy; Non small cell lung cancer; Pneumonectomy; Positive mediastinal lymph nodes; Stage IIIA N2

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MORBIDITY; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDIASTINUM; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PNEUMONECTOMY; PROGNOSIS; TREATMENT OUTCOME;

EID: 68749106139     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2009.04.013     Document Type: Article

References (28)

1. Johnson D.H., Rusch V.W., and Turrisi A.T. Scalpels, beams, drugs, and dreams: challenges of stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99 6 (2007) 415-418
2. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 6 (1997) 1710-1717
3. Detterbeck F.C., Jantz M.A., Wallace M., Vansteenkiste J., and Silvestri G.A. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 3 Suppl. (2007) 202S-220S
4. Andre F., Grunenwald D., Pignon J.P., Dujon A., Pujol J.L., Brichon P.Y., Brouchet L., Quoix E., Westeel V., and Le Chevalier T. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18 16 (2000) 2981-2989
5. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., Stalpaert G., Nackaerts K.L., Lerut T.E., Demedts M.G., and Leuven Lung Cancer Group. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg 63 5 (1997) 1441-1450
6. Alberts W.M. Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 3 Suppl. (2007) 1S-19S
7. Cerfolio R.J., and Bryant A.S. Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. Ann Thorac Surg 86 2 (2008) 362-366
8. Detterbeck F. What to do with "surprise" N2?: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol 3 3 (2008) 289-302
9. Betticher D.C., Hsu Schmitz S.F., Totsch M., Hansen E., Joss C., von Briel C., Schmid R.A., Pless M., Habicht J., Roth A.D., Spiliopoulos A., Stahel R., Weder W., Stupp R., Egli F., Furrer M., Honegger H., Wernli M., Cerny T., and Ris H.B. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA PN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 21 9 (2003) 1752-1759
10. Eberhardt W., Wilke H., Stamatis G., Stuschke M., Harstrick A., Menker H., Krause B., Mueller M.R., Stahl M., Flasshove M., Budach V., Greschuchna D., Konietzko N., Sack H., and Seeber S. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 16 2 (1998) 622-634
11. Lorent N., De Leyn P., Lievens Y., Verbeken E., Nackaerts K., Dooms C., Van Raemdonck D., Anrys B., and Vansteenkiste J. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 15 11 (2004) 1645-1653
12. Dooms C., Verbeken E., Stroobants S., Nackaerts K., De Leyn P., and Vansteenkiste J. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 26 7 (2008) 1128-1134
13. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., van Oosterom A.T., Christian M.C., and Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
14. Lardinois D., De Leyn P., Van Schil P., Porta R.R., Waller D., Passlick B., Zielinski M., Lerut T., and Weder W. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 30 5 (2006) 787-792
15. Rami-Porta R., Wittekind C., and Goldstraw P. Complete resection in lung cancer surgery: proposed definition. Lung Cancer 49 1 (2005) 25-33
16. De Leyn P., Stroobants S., De Wever W., Lerut T., Coosemans W., Decker G., Nafteux P., Van Raemdonck D., Mortelmans L., Nackaerts K., and Vansteenkiste J. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a leuven lung cancer group study. J Clin Oncol 24 21 (2006) 3333-3339
17. Betticher D.C., Hsu Schmitz S.F., Totsch M., Hansen E., Joss C., von Briel C., Schmid R.A., Pless M., Habicht J., Roth A.D., Spiliopoulos A., Stahel R., Weder W., Stupp R., Egli F., Furrer M., Honegger H., Wernli M., Cerny T., and Ris H.B. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA PN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 94 8 (2006) 1099-1106
18. Albain K.S., Swann R.S., Rusch V.R., Turrisi A.T., Shepherd F.A., Smith C.J., Gandara D.R., Johnson D.H., Green M.R., Miller R.C., and North American Lung Cancer Intergroup. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(PN2) non-small cell lung cancer (NSCLC): outcomes update of North American intergroup 0139 (RTOG 9309). J Clin Oncol 23 16_Suppl. (2005) 7014 [Meeting Abstracts]
19. Van Meerbeeck J.P., Kramer G.W., Van Schil P.E., Legrand C., Smit E.F., Schramel F., Tjan-Heijnen V.C., Biesma B., Debruyne C., van Zandwijk N., Splinter T.A., and Giaccone G. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99 6 (2007) 442-450
20. Massard G., Kessler R., and Wihlm J.M. Improved selection of winners: a working hypothesis for neoadjuvant chemotherapy. Ann Thorac Surg 66 1 (1998) 300-301
21. Barlesi F., Doddoli C., Torre J.P., Giudicelli R., Fuentes P., Thomas P., and Astoul P. Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy. Eur J Cardiothorac Surg 28 4 (2005) 629-634
22. Bueno R., Richards W.G., Swanson S.J., Jaklitsch M.T., Lukanich J.M., Mentzer S.J., and Sugarbaker D.J. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 70 6 (2000) 1826-1831
23. Martin J., Ginsberg R.J., Venkatraman E.S., Bains M.S., Downey R.J., Korst R.J., Kris M.G., and Rusch V.W. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol 20 8 (2002) 1989-1995
24. Port J.L., Korst R.J., Lee P.C., Levin M.A., Becker D.E., Keresztes R., and Altorki N.K. Surgical resection for residual N2 disease after induction chemotherapy. Ann Thorac Surg 79 5 (2005) 1686-1690
25. Rusch V.W., Crowley J., Giroux D.J., Goldstraw P., Im J.G., Tsuboi M., Tsuchiya R., and Vansteenkiste J. The IASLC lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2 7 (2007) 603-612
26. Cerfolio R.J., Maniscalco L., and Bryant A.S. The treatment of patients with stage IIIa non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg 86 3 (2008) 912-920
27. Ichinose Y., Kato H., Koike T., Tsuchiya R., Fujisawa T., Shimizu N., Watanabe Y., Mitsudomi T., Yoshimura M., and Tsuboi M. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. J Thorac Cardiovasc Surg 122 4 (2001) 803-808
28. Goldstraw P. Selection of patients for surgery after induction chemotherapy for N2 Non-small-cell lung cancer. J Clin Oncol 24 21 (2006) 3317-3318